Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Melinta Therapeutics Inc (MLNT)

Melinta Therapeutics Inc (MLNT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Melinta Therapeutics Inc 44 WHIPPANY ROAD MORRISTOWN NJ 07960 USA

www.melinta.com P: 908-617-1309

Description:

Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT.

Key Statistics

Overview:

Market Capitalization, $K 6,050
Shares Outstanding, K 13,751
Annual Sales, $ 96,430 K
Annual Net Income, $ -157,190 K
Last Quarter Sales, $ 15,870 K
Last Quarter Net Income, $ -213,380 K
60-Month Beta 4.16
% of Insider Shareholders 60.30%
% of Institutional Shareholders 18.02%
Float, K 5,459
% Float 39.70%

Growth:

1-Year Return -91.70%
3-Year Return -99.41%
5-Year Return -99.93%
5-Year Revenue Growth 1,134.70%
5-Year Earnings Growth 53.67%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 11/13/19
Earnings Per Share ttm -9.47
EPS Growth vs. Prev Qtr 30.62%
EPS Growth vs. Prev Year 14.80%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-5 on 02/22/19

MLNT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -101.29%
Return-on-Assets % -28.69%
Profit Margin % -163.01%
Debt/Equity -2.52
Price/Sales 0.07
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -4.40
Interest Coverage -2.64
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar